Source comparison
Mechanism of Action: GABA Modulation vs BDNF Upregulation
Selank operates through GABAergic pathway enhancement. It does not bind GABA receptors directly but modulates enkephalin metabolism, which in turn potentiates GABA signaling in the amygdala and prefrontal cortex. Preclinical models show Selank increases endoge
This comparison does not assign a generated winner or score.
- Selank operates through GABAergic pathway enhancement. It does not bind GABA receptors directly but modulates enkephalin metabolism, which in turn potentiates GABA signaling in the amygdala and prefrontal cortex. Preclinical models show Selank increases endogenous met-enkephalin levels by 15–22%, reducing hypothalamic-pituitary-adrenal (HPA) axis activation under stress. This is mechanistically distinct from benzodiazepines, which agonize GABA-A receptors. Selank's effect is modulatory, not agonistic, meaning it does not produce receptor downregulation or withdrawal symptoms observed with long-term benzodiazepine use.
- Semax functions through brain-derived neurotrophic factor (BDNF) expression. Animal studies published in Neuroscience Letters demonstrated 40–60% increases in hippocampal BDNF mRNA within 24 hours of Semax administration. BDNF drives synaptic plasticity, neurogenesis, and dendritic spine formation. The structural basis for learning and memory consolidation. Semax additionally modulates dopamine and serotonin metabolism in the striatum and nucleus accumbens, which contributes to its reported cognitive stimulant effects. The compound does not act as a direct monoamine reuptake inhibitor. It upregulates tyrosine hydroxylase and tryptophan hydroxylase, the rate-limiting enzymes in dopamine and serotonin synthesis respectively.
- The amidate modification. Replacing the terminal carboxyl group with an amide. Extends peptide half-life from approximately 30 minutes (for non-amidated forms) to 90–120 minutes by blocking carboxypeptidase degradation. This triples effective bioavailability without altering receptor binding affinity. Research teams selecting between Selank and Semax should prioritise mechanism over half-life. The amidate form is standard for both peptides in current research protocols.